Triple therapy targets tough lung cancer
NCT ID NCT05003037
First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time
Summary
This phase II trial is testing whether a combination of surufatinib (a targeted therapy), toripalimab (an immunotherapy), and standard chemotherapy can help people with advanced non-squamous non-small cell lung cancer. The study enrolls adults with stage IIIB or IV disease who have not had prior treatment. Researchers are measuring how long the cancer stays under control and tracking side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- surufatinib, toripalimab, pemetrexed, carboplatin/cisplatin
- What this could lead to
- If successful, this combination could offer a new treatment option for people with advanced non-squamous non-small cell lung cancer, potentially improving how long they live without their cancer growing.
- What could go wrong
- This is a phase II trial, so the combination is still being tested for safety and effectiveness. It may not work better than existing treatments, and side effects from combining multiple drugs could be significant.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Chest-Injected drug drain Cancer's fluid trap?
- Can a radioactive tracer reveal whether immunotherapy is working?
- Can a new nucleotide analogue boost cancer treatment?
- Can a pill that blocks multiple cancer proteins shrink Hard-to-Treat tumors?
- Can a Two-Pronged attack shrink Hard-to-Treat cancers?
- Can standard cancer treatment wake up the immune system? a study investigates.